Study finds no beta-cell benefits with canakinumab, anakinra

04/17/2013 | Healio

Neither canakinumab nor anakinra fared better than placebo in delaying beta-cell dysfunction in patients with new-onset type 1 diabetes, a study in The Lancet found. Researchers also noted a greater prevalence of adverse events in patients who took anakinra compared with those in the placebo group.

View Full Article in:

Healio

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Corporate Counsel - Healthcare Law Group
Genentech
South San Francisco, CA
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC